RT Journal Article
SR Electronic
T1 Dupilumab reduces severe exacerbation-related costs among asthma patients: Results from a phase 2b trial
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA1530
DO 10.1183/13993003.congress-2016.PA1530
VO 48
IS suppl 60
A1 Jonathan Corren
A1 Pascal Chanez
A1 Mario Castro
A1 Leonardo Fabbri
A1 Vijay N. Joish
A1 Robert E. Evans
A1 Neil M.H. Graham
A1 Vera Mastey
A1 Sara Villeneuve
A1 Gaëlle Bégo-Le Bagousse
A1 Christine Taniou
A1 Puneet Mahajan
A1 Ariel Teper
A1 Gianluca Pirozzi
A1 Laurent Eckert
YR 2016
UL http://erj.ersjournals.com/content/48/suppl_60/PA1530.abstract
AB Rationale: In a phase 2b trial (NCT01854047), dupilumab (DPL) improved lung function and reduced severe exacerbations. This sub-analysis estimated severe exacerbation-related direct medical and productivity-related costs.Methods: Uncontrolled persistent asthma pts on medium-to-high-dose ICS/LABA were randomized to 24 weeks of add-on therapy with DPL 200mg every 2 weeks (q2w), 300mg q2w, 200mg every 4 weeks (q4w), 300mg q4w, or placebo (PBO). Healthcare resource utilization, work and non-work related days lost were collected using a questionnaire and monetized using published costs. Results are presented for the q2w and PBO groups only; q2w regimens have been selected for dosing in a phase 3 trial.Results: Compared with PBO, both DPL groups had lower numbers of hospitalizations, inpatient days, unscheduled physician visits, as well as work and non-work-related days lost. The 300mg group had lower number of emergency room visits while the 200mg group was similar to PBO. Total direct medical and productivity-related costs were lower for the DPL groups (Table). Severe exacerbation-related costs were 52% and 84% lower, respectively, in the DPL q2w groups vs PBO. Most common adverse events with DPL vs PBO were upper respiratory tract infection (13–15% vs 18%) and injection-site erythema (14–22% vs 8%).Conclusions: Dupilumab-treated patients had lower severe exacerbation-related costs compared to PBO.